Verve Therapeutics, Inc. (VERV)

5,98 -0,03 (-0,50%) In data: 12:41PM EDT. Mercato aperto.

Verve Therapeutics, Inc.

201 Brookline Avenue
Suite 601
Cambridge, MA 02215
United States
617 603 0070
https://www.vervetx.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 255

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Sekar Kathiresan M.D.	Co-Founder, CEO & Director	973,25k	N/D	1973
Ms. Joan Nickerson M.B.A.	Chief Administrative Officer	N/D	N/D	1969
Ms. Jennifer Robinson	Vice President of Investor Relations & Corporate Communications	N/D	N/D	N/D
Ms. Kaitlin Duffy	Executive Director of Human Resources	N/D	N/D	N/D
Mr. Yasser M. El-Gamal J.D.	Senior VP of Legal Affairs & Chief Intellectual Property Counsel	N/D	N/D	1968
Mr. Jason Politi	Chief Technical Operations Officer	N/D	N/D	1977
Dr. Troy Lister Ph.D.	Senior Vice President of Research & Early Development	N/D	N/D	N/D
Dr. Leslie Stolz Ph.D.	Senior Vice President of Regulatory Affairs	N/D	N/D	N/D
Ms. Jaime Kirk	Controller	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Verve Therapeutics, Inc. al 29 aprile 2024 è 8. I criteri di valutazione fondamentali sono revisione: 7; Consiglio di Amministrazione: 8; diritti degli azionisti: 8; retribuzione: 7.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.